Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

Bake Sale in support of the UK Sepsis Trust

Bake Sale in support of the UK Sepsis Trust
Created on 20-09-2019

MediSieve held a charity bake sale to support the UK Sepsis Trust on the World Sepsis Day. 
MediSieve shortlisted for 2019 Emerging Technologies Competition, run by the Royal Society of Chemistry

MediSieve shortlisted for 2019 Emerging Technologies Competition, run by the Royal Society of Chemistry
Created on 06-09-2019

MediSieve was shortlisted for the final round of 2019 Emerging Technology Competition, run by the R...